Juan Antonio Castillo

Jefe de Servicio de Cardiología. Hospital Santa Lucía, Cartagena. Región de Murcia.

[SABOURETCardiologist @SABOURETCardio]

Atherogenic responsibility of lipoprotein (a) and other apolipoprotein B-containing lipoproteins in #ACS- Atherosclerosis https://t.co/6fyHnn34qD

[Juan Antonio Castillo @JACastilloMo]

Cerramos nuestra participación en #SEC25 con la comunicación "Importancia de colesterol HDL y lipoproteina (a) en el perfil de riesgo cardiovascular del paciente
con síndrome coronario agudo recurrente", que presenta @franbuendia97 @J_M_Andreu @ameseguer97 @PatonRubio @SMurCardio

[Juan Antonio Castillo @JACastilloMo]

Otra gran jornada de los resis de Cardio del H Stª Lucía @Area2Cartagena en el Congreso #SEC25 a los que se ha sumado nuestra excelente enfermera de IC @ameseguer97 @franbuendia97 @J_M_Andreu @SMurCardio @sedes_jose @PatonRubio @Doctorabellan @secardiologia

[Juan Antonio Castillo @JACastilloMo]

¡Que bien han defendido los resis de Cardio del Hospital Stª Lucía @Area2Cartagena sus comunicaciones orales durante la primera joranada de #SEC25 ! Mañana más... @franbuendia97 @J_M_Andreu @SMurCardio @Doctorabellan @PatonRubio @secardiologia

[Juan Antonio Castillo @JACastilloMo]

Atherosclerosis publishes our study (Cardiology & Clinical Lab, Hospital St. Lucía @Area2Cartagena @franbuendia97 @J_M_Andreu @ameseguer97 @Cardiogarcia @Doctorabellan @_rMarmol_ @DrDau3 @SMurCardio @secardiologia

[Juan Antonio Castillo @JACastilloMo]

ATHEROGENIC RESPONSIBILITY OF LIPOPROTEIN (a) AND OTHER APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS IN ACUTE CORONARY SYNDROME. - Atherosclerosis https://t.co/UYgOf6alU5

[Juan Antonio Castillo @JACastilloMo]

Atherosclerosis publishes our study (Cardiology & Clinical Lab, Hospital St. Lucía @area2Cartagena)
"Atherogenic responsibility of lipoprotein (a) and other apolipoprotein B-containing lipoproteins in acute coronary syndrome" @franbuendia97 @J_M_Andreu @ameseguer97 @SMurCardio

[Soc Esp Cardiología @secardiologia]

.@ameseguer97: El estudio AQUATIC, primer ensayo aleatorizado y doble ciego en este campo, aclara la duda existente en el balance entre el riesgo hemorrágico y aterotrombótico: menos es más". #BlogSEC @jovenesSEC https://t.co/OaT1cdhTxA

[John Mandrola, MD @drjohnm]

The AQUATIC trial may be the most definitive trial of #ESCCOngress

The common combo of ASA and OAC for pts with CAD/stent and AF is clearly been harming people. Lots.

MACE worse, Death worse, Bleeding way worse.

STOP THE ASA when on OAC

https://t.co/OSx0UKWPXe

[The Lancet @TheLancet]

Presenting at #ESCCongress: Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials https://t.co/bkA4ZwtbtB

[The Lancet @TheLancet]

Presenting at #ESCCongress: Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial https://t.co/0TVRuw8Uzf

[NEJM @NEJM]

Presented at #ESCCongress:

Among patients with myocardial infarction and a left ventricular ejection fraction of more than 40%, beta-blockers did not lead to a lower incidence of death, reinfarction, or hospitalization for heart failure than no beta-blocker therapy. Full REBOOT trial results: https://t.co/bCQMwqvcai

@escardio

[NEJM @NEJM]

Presented at #ESCCongress:

Among patients with myocardial infarction and a left ventricular ejection fraction of at least 40%, beta-blockers led to a lower risk of death or major cardiovascular events than no beta-blocker therapy. Full BETAMI–DANBLOCK trial results: https://t.co/ZCfkG7tpBI

@escardio

[NEJM @NEJM]

Original Article: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias (POTCAST trial) https://t.co/6HUcV2CkKq

#ESCCongress | @escardio

[NEJM @NEJM]

Presented at #ESCCongress:

In patients with STEMI with cardiogenic shock, early mechanical support with a microaxial pump reduced the risk of death at 180 days, with the survival benefit persisting up to 10 years despite device-related complications. Full DanGer Shock trial results: https://t.co/BYPnBqr6vN

@escardio

[NEJM @NEJM]

Original Article: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation (AQUATIC trial) https://t.co/vHYyFalktf

#ESCCongress | @escardio

[NEJM @NEJM]

Original Article: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes (NEO-MINDSET trial) https://t.co/IA8PpmkF2U

#ESCCongress | @escardio

[NEJM @NEJM]

Original Article: Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction (TARGET-FIRST trial) https://t.co/lUQPGy5Xwh

#ESCCongress | @escardio

[NEJM @NEJM]

Original Article: Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome (TACSI trial) https://t.co/dnIiQbX1qF

#ESCCongress | @escardio

[NEJM @NEJM]

Among patients with myocardial infarction and a left ventricular ejection fraction of at least 40%, beta-blockers led to a lower risk of death or major cardiovascular events than no beta-blocker therapy. Full BETAMI–DANBLOCK trial results and Research Summary: https://t.co/ZCfkG7tpBI